What are Aromatase Inhibitors?

Aromatase inhibitors are a class of hormonal agents that form part of the therapy for some types of breast cancer. These agents are available as pills and may be started after initial surgery or radiation therapy.


The aromatase inhibitors include anastrozole (Armidex), letrozole (Femara) and exemastane (Aromasin).

Mechanism of action

The enzyme aromatase works alongside NADPH (nicotinamide adenine dinucleotide phosphate) to convert male hormones or androgens to estrogens. Specifically, androstenedione and testosterone are converted to estrone and estradiol. Aromatase inhibitors prevent the formation of estrogen and thus reduce the estrogen dependent growth of estrogen receptor (ER) positive cancers.


Aromatase inhibitors are useful in women who have already experienced the menopause and have ER-positive tumors. Since postmenopausal women have small and shrunken ovaries that produce low levels of estrogen, use of aromatase inhibitors may further prevent estrogen production and its stimulation of the tumour growth.

However, among premenopausal who have these ER-positive tumours, the ovaries still produce estrogen at levels which mean aromatase inhibitors will not be able to inhibit tumour growth.

Advantages of using aromatase inhibitors

The advantages of using aromatase inhibitors over other hormonal agents such as tamoxifen include a decrease in vaginal discharge, a reduced risk of blood clotting and less risk of womb cancer.

Side effects

The side effects of taking aromatase inhibitors include:

  • Pain in the muscles and joints
  • Osteoporosis, brittle bones and fractures resulting from minor traumas
  • Confusion and memory impairment


The aromatase inhibitors anastrozole and letrozole are similar in their pharmacokinetic properties and both have a dosing schedule of once daily due to a half life (time taken for a the amount of a drug present in the body to become halved) of approximately 48 hours for each of them. The half life of exemestane on the other hand, is 24 hours.

Further Reading

Last Updated: Feb 26, 2019

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2019, February 26). What are Aromatase Inhibitors?. News-Medical. Retrieved on August 01, 2021 from https://www.news-medical.net/health/What-are-Aromatase-Inhibitors.aspx.

  • MLA

    Mandal, Ananya. "What are Aromatase Inhibitors?". News-Medical. 01 August 2021. <https://www.news-medical.net/health/What-are-Aromatase-Inhibitors.aspx>.

  • Chicago

    Mandal, Ananya. "What are Aromatase Inhibitors?". News-Medical. https://www.news-medical.net/health/What-are-Aromatase-Inhibitors.aspx. (accessed August 01, 2021).

  • Harvard

    Mandal, Ananya. 2019. What are Aromatase Inhibitors?. News-Medical, viewed 01 August 2021, https://www.news-medical.net/health/What-are-Aromatase-Inhibitors.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit